Inventor

Chien-Hsing Chang

Inventor

Downingtown, PA, US

Overview

1994–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 149 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary

A61KPreparations for medical, dental or toiletry purposes25%

C07KPeptides25%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations18%

B82YSpecific uses or applications of nanostructures10%

C12NMicroorganisms or enzymes8%

C12YEnzymes3%

G01NInvestigating or analysing materials by determining their chemical or physical properties3%

Y02ATechnologies for adaptation to climate change2%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture2%

C08BPolysaccharides1%

PatentTitleYear

10,669,338Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-12020 10,662,252Disease therapy by inducing immune response to Trop-2 expressing cells2020 10,436,788Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells2019 10,385,139Murine, chimeric, humanized or human anti-TNF-alpha antibodies2019 10,377,829Isolated nucleic acid encoding an anti-IGF-1R antibody2019 10,308,688T-cell redirecting bispecific antibodies for treatment of disease2019 10,245,321Combination therapy for inducing immune response to disease2019 10,239,938T-cell redirecting bispecific antibodies for treatment of disease2019 10,183,992T-cell redirecting bispecific antibodies for treatment of disease2019 10,174,114Humanized anti-HLA-DR antibodies2019 10,160,801Nucleic acids encoding chimeric and humanized anti-histone antibodies2018 10,131,712Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors2018 10,111,954Combination therapy for inducing immune response to disease2018 10,040,848Chimeric and humanized anti-histone antibodies2018 10,022,427Interferon lambda-antibody complexes2018 9,993,547T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines2018 9,963,507Therapeutic use of anti-CD22 antibodies for inducing trogocytosis2018 9,944,703Humanized anti-CD22 antibody2018 9,931,413Tetrameric cytokines with improved biological activity2018 9,932,413Murine, chimeric, humanized or human anti-IL-6 antibodies2018 9,920,116'Methods for treating ischemic stroke using chimeric and humanized anti-histone antibodies'2018 9,879,088'Disease therapy by inducing immune response to Trop-2 expressing cells'2018 9,872,920PEGylation by the dock and lock (DNL) technique2018 9,862,770'Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors'2018 9,839,689'Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy'2017 9,809,646'Methods for treating thrombosis using chimeric and humanized anti-histone antibodies'2017 9,797,907'Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells'2017 9,757,458'Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells'2017 9,751,948'Class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type I receptor (IGF-1R)'2017 9,745,374'Fusion proteins containing recombinant cytotoxic RNAses'2017 9,737,617'Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2017 9,707,300'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'2017 9,701,748'Humanized anti-CD22 antibody'2017 9,687,547'T20 constructs for anti-HIV (human immunodeficiency virus) therapy and/or vaccines'2017 9,682,143'Combination therapy for inducing immune response to disease'2017 9,670,286'Disease therapy by inducing immune response to Trop-2 expressing cells'2017 9,663,576'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2017 9,657,093'Methods for treating sepsis using chimeric and humanized anti-histone antibodies'2017 9,623,115'Dock-and-Lock (DNL) Complexes for Disease Therapy'2017 9,617,531'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock'2017 9,599,619'Anti-pancreatic cancer antibodies'2017 9,555,661'Electric pencil sharpener with a replaceable cutter assembly'2017 9,550,838'Dock-and-lock (DNL) complexes for therapeutic and diagnostic use'2017 9,540,435'Stably tethered structures of defined compositions with multiple functions or binding specificities'2017 9,540,618'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2017 9,518,115'Humanized anti-CD22 antibody'2016 9,498,542'Tetrameric cytokines with improved biological activity'2016 9,492,561'Dock-and-Lock (DNL) Complexes for delivery of interference RNA'2016 9,481,878'Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity'2016 9,475,883'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2016 9,457,100'PEGylation by the dock and lock (DNL) technique'2016 9,457,072'Dock-and-lock (DNL) vaccines for cancer therapy'2016 9,452,228'Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)'2016 9,446,123'Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy'2016 9,441,043'Methods of treating cancer with antibodies that target the insulin-like growth factor type I receptor (IGF-1R)'2016 9,416,197'Bispecific antibodies that neutralize both TNF-Î± and IL-6: novel therapeutic agent for autoimmune disease'2016 9,382,329'Disease therapy by inducing immune response to Trop-2 expressing cells'2016 9,371,393'Class I anti-CEA antibodies and uses thereof'2016 9,359,443'Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases'2016 9,352,036'Delivery system for cytotoxic drugs by bispecific antibody pretargeting'2016 9,315,567'T-cell redirecting bispecific antibodies for treatment of disease'2016 9,278,129'Methods of treating rapidly progressive glomerulonephritis using chimeric and humanized anti-histone H4 antibodies'2016 9,272,029'Interferon lambada-antibody complexes'2016 9,248,184'Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy'2016 9,238,084'Anti-mucin antibodies for early detection and treatment of pancreatic cancer'2016 9,192,664'Therapeutic use of anti-CD22 antibodies for inducing trogocytosis'2015 9,187,561'Humanized anti-HLA-DR antibodies'2015 9,184,781'Humanized antibodies and methods of humanizing antibodies'2015 9,169,470'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2015 9,149,921'Flat-clinch stapler having a buffering device'2015 9,139,657'Class I anti-CEA antibodies and uses thereof'2015 9,139,649'Humanized anti-CD22 antibody'2015 9,005,613'Anti-mucin antibodies for early detection and treatment of pancreatic cancer'2015 8,992,917'Humanized L243 antibodies'2015 8,986,699'Anti-CD74 immunoconjugates and methods of use'2015 8,987,421'Chimeric and humanized anti-histone antibodies'2015 8,974,784'Anti-pancreatic cancer antibodies'2015 8,945,554'Class I anti-CEA antibodies and uses thereof'2015 8,932,593'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2015 8,906,377'Stably tethered structures of defined compositions with multiple functions or binding specificities'2014 8,906,378'Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases'2014 8,889,410'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2014 8,889,835'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'2014 8,883,162'Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors'2014 8,883,160'Dock-and-lock (DNL) complexes for therapeutic and diagnostic use'2014 8,871,216'Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2014 8,865,176'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2014 8,829,175'Nucleic acids encoding polyvalent protein complexes'2014 8,821,868'Anti-pancreatic cancer antibodies'2014 8,771,690'Class I anti-CEA antibodies and uses thereof'2014 8,771,987'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2014 8,722,047'Humanized anti-HLA-DR antibodies'2014 8,697,080'Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments'2014 8,652,484'Delivery system for cytotoxic drugs by bispecific antibody pretargeting'2014 8,613,903'Humanized L243 antibodies'2013 8,603,479'Class I anti-CEA antibodies and uses thereof'2013 8,597,659'Tetrameric cytokines with improved biological activity'2013 8,569,054'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2013 8,562,988'Strategies for improved cancer vaccines'2013 8,551,480'Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity'2013 8,491,896'Anti-pancreatic cancer antibodies'2013 8,491,914'Dock-and-lock (DNL) complexes for delivery of interference RNA'2013 8,481,041'Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy'2013 8,475,794'Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases'2013 8,470,994'Class I anti-CEA antibodies and uses thereof'2013 8,435,539'Delivery system for cytotoxic drugs by bispecific antibody pretargeting'2013 8,435,540'Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO'2013 8,383,081'Anti-CD74 immunoconjugates and methods of use'2013 8,372,603'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2013 8,349,332'Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases'2013 8,338,140'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'2012 8,333,971'Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments'2012 8,287,865'Class I anti-CEA antibodies and uses thereof'2012 8,287,864'Structural variants of antibodies for improved therapeutic characteristics'2012 8,282,934'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology'2012 8,277,817'PEGylation by the dock and lock (DNL) technique'2012 8,246,960'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2012 8,211,440'Multivalent immunoglobulin-based bioactive assemblies'2012 8,192,739'Fusion proteins containing recombinant cytotoxic RNAses'2012 8,163,291'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2012 8,158,129'Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo'2012 8,153,433'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2012 8,097,252'Methods and compositions for administering therapeutic and diagnostic agents'2012 8,076,140'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2011 8,067,006'Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites'2011 8,034,352'Tetrameric cytokines with improved biological activity'2011 8,003,111'Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo'2011 7,981,398'PEGylation by the dock and lock (DNL) technique'2011 7,932,212'Inhibition of placenta growth factor (PlGF) mediated metastasis and/or angiogenesis'2011 7,919,273'Structural variants of antibodies for improved therapeutic characteristics'2011 7,906,121'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2011 7,906,118'Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology'2011 7,901,680'Dock-and-lock (DNL) vaccines for cancer therapy'2011 7,892,547'Methods and compositions for administering therapeutic and diagnostic agents'2011 7,871,622'Stably tethered structures of defined compositions with multiple functions or binding specificities'2011 7,858,070'Multivalent immunoglobulin-based bioactive assemblies'2010 7,785,880'Mammalian cell lines for increasing longevity and protein yield from cell culture'2010 7,666,400'PEGylation by the dock and lock (DNL) technique'2010 7,642,239'Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis'2010 7,608,425'Methods for protein expression in mammalian cells in serum-free medium'2009 7,550,143'Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses'2009 7,544,487'Fusion proteins containing recombinant cytotoxic RNAses'2009 7,537,930'Mammalian cell lines for increasing longevity and protein yield from a cell culture'2009 7,534,866'Methods and compositions for generating bioactive assemblies of increased complexity and uses'2009 7,534,431'Methods and compositions for administering therapeutic and diagnostic agents'2009 7,531,327'Methods and compositions for increasing longevity and protein yield from a cell culture'2009 7,527,787'Multivalent immunoglobulin-based bioactive assemblies'2009 7,521,056'Stably tethered structures of defined compositions with multiple functions or binding specificities'2009 5,334,708'Method for radiolabeling monovalent antibody fragments'1994

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1994–2020Patents assigned to IMMUNOMEDICS INC (79)· patent assignee history

1994–2020Based in Downingtown, PA, US· patent location history

2009–2020Patents assigned to IBC PHARMACEUTICALS INC (71)· patent assignee history

2009–2016Based in Downington, PA, US· patent location history

2009Based in Dowinngtown, PA, US· patent location history

2011–2017Patents assigned to GOLDENBERG DAVID M (40)· patent assignee history

2011–2017Patents assigned to CHANG CHIEN-HSING (37)· patent assignee history

2011–2017Patents assigned to ROSSI EDMUND A (23)· patent assignee history

2013Based in Dowingtown, PA, US· patent location history

2015–2017Based in Chang Hua Hsien, TW· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
IMMUNOMEDICS INC	79	1994–2020
IBC PHARMACEUTICALS INC	71	2009–2020
GOLDENBERG DAVID M	40	2011–2017
CHANG CHIEN-HSINGself	37	2011–2017
ROSSI EDMUND A	23	2011–2017

Locations

Location	Patents	Span
Downingtown, Pennsylvania, US	138	1994–2020
Downington, Pennsylvania, US	6	2009–2016
Chang Hua Hsien, TW	2	2015–2017
Dowingtown, Pennsylvania, US	2	2013
Dowinngtown, Pennsylvania, US	1	2009